PA GOODDOCTOR

1833
5.3050.56% ( -0.030 )
Delay Closed: Nov 16, 16:08:11

Overview

PA GOODDOCTOR (1833)

Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in China. It offers online di...

Open
5.335
High
5.425
Low
5.285
Prev. Close
5.335
Volume
6.73M
Turnover
35.91M
Avg Price
5.333
Bid/Ask Ratio
-56.94%
Amplitude
2.62%
52wk High
18.790
Volume Ratio
0.48
Turnover Ratio
0.31%
52wk Low
5.245
HK Mkt Cap
11.47B
Market CapHKD
11.47B
P/ETTM
22.18
P/EDynamic
29.74
P/EStatic
--
EPSTTM
0.239
EPSDynamic
0.178
EPSStatic
--
BVPS
5.37
P/B
0.99
HK Shares
2.16B
Dividend YieldTTM
--
DividendTTM
--
Shares
2.16B
Min lot size
100
Currency
HKD

PA GOODDOCTOR Analyst Rating

View more

Forecast & Rating

Oct 27, 2026
Price forecast
HK$9.8585.72%
Forecast & RatingBuy
15analysts
  • Strong buy33.33%
  • Buy13.33%
  • Hold46.67%
  • Sell0.00%
  • Strong sell6.67%

Daily Events

  1. Nov, 16

    Ping An Health slipped 0.56% to HK$5.305 today, pressured by multiple corporate developments overlaid on bullish earnings. Nine-month net profit rose 35% YoY; Q2 was especially strong with net profit HK$126.7M (+72.32% YoY), operating profit HK$122.8M (+98.6% YoY jump), and EPS HK$0.0578 (+56.22% YoY). Most brokerages maintain buy ratings. However, the company announced in early November both a headquarters relocation to Shenzhen (effective November 23) and a request for shareholder approval to renew connected transactions, creating incremental governance uncertainty. Price action reflects this mixed picture: the stock sits just 1.14% above its 52-week low of HK$5.245 and down 63.61% year-to-date from HK$14.58, trading below its 20-day moving average of HK$5.584. Investors await clarity on the shareholder vote and whether profit momentum can sustain.

  2. Nov, 13

    PA Good Doctor closed down 3.78% at HKD5.335, with intraday reversal (peak HKD5.535 at 10:50 AM) as profit-taking dominated the afternoon session. The company recently reported 9-month results with net profit surging 35% YoY, while Q1-Q2 EPS each advanced over 56% with Q2 reaching HKD0.0578, a new high; revenue growth remained subdued at only 4-5% to RMB14.1-14.3 billion with stable 8.83% net margin. Despite the strong earnings momentum, the stock has plummeted 63.41% year-to-date and now trades within 1.72% of its 52-week low, well below both 20- and 60-day moving averages—signaling continued market caution over profit sustainability. Concurrently, the company is seeking shareholder approval to renew connected transactions material to its healthcare operations.

  3. Nov, 12

    Ping An Healthcare declined approximately 3.8% to HK$5.545 today, primarily driven by profit-taking pressure following recent gains. The company's nine-month cumulative net profit reached RMB 248.21 million, up 35% year-over-year, with Q2 single-quarter EPS of HK$0.0578, up 56.22% YoY. However, the stock has sharply diverged from fundamentals, plunging 61.97% year-to-date from HK$14.58 to the current HK$5.545, down 70.49% from the 52-week high of HK$18.79 and trading just 5.72% above the 52-week low of HK$5.245, well below its 60-day moving average of HK$6.043. CICC analysts maintain a Buy rating on the company, while management announced plans to relocate the headquarters to Shenzhen effective Nov. 23 and seeks shareholder approval to renew connected transactions.

  4. Nov, 11

    Ping An Healthcare fell 3.44% to HK$5.765 today, extending a year-to-date downturn that has been pressuring the stock since early January, with the morning session declining from an opening of HK$5.860 to 5.800 by late morning, while the afternoon session briefly recovered to 5.830 but ultimately settled near the day's lows at 5.765. This reflects the broader pullback in the stock's price from its peak—shares have plummeted 60.46% year-to-date, dropping from the 52-week high of HK$18.79 (hit on Jan 13) to current levels, representing a 69.32% decline; although the stock rebounded roughly 9.91% from the 52-week low of HK$5.245 hit in late October, selling pressure persists. Despite the price weakness, the company's recent operational performance remains solid, with nine-month net profit up 35% year-over-year and the latest two consecutive quarters delivering EPS growth of 56-57% yoy, signaling accelerating earnings; the company is trading at a PE of 24.1x and is progressing with related-party transaction renewals.

  5. Nov, 10

    1833.HK extended its rally to close at HK$5.97, up 3.73%, following yesterday's sharp 9.03% surge. The morning session started firm at 5.865 but retreated to a low of 5.795 before stabilizing; afternoon trading from 13:00 onward gathered strength, with the stock climbing to a session high of 5.97 by the 16:00 close. The rebound is underpinned by robust earnings: the nine-month results released in mid-October show net profit growth of 35% year-over-year, with Q2 posting a 72.32% YoY jump in net profit and a 97.39% surge in operating profit, while EPS expanded roughly 56% YoY and revenue remained steady (4-5% YoY growth over the same six months). Nevertheless, the stock has plummeted 59.05% year-to-date from its January opening of HK$14.58, and sits 68.23% below its 52-week peak of HK$18.79; having rebounded from the 52-week low of HK$5.245 on 29 October, the durability of this bounce requires further validation. The stock now trades above its 20-day moving average with a P/E multiple of 24.95x.

News

Bullish vs. Bearish — Last 3 Months

6.8k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • M
    momoM

    $XTALPI(02228.HK) Goldman Sachs launched the "China AI Healthcare Index" today, with Pharmaron as the top-weighted stock $ALI HEALTH(00241.HK)$JD HEALTH(06618.HK)$PA GOODDOCTOR(01833.HK)$YIDU TECH(02158.HK)$MircroPort Medbot-B(02252.HK)

    图片 1,共 1 张